Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting

Presentations include positive preclinical toxicology results, quality-of-life data and physician OFF episode treatment practices

TORONTO, May 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics, Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), today announced that three clinical posters will be presented today at the 2nd Congress of the European Academy of Neurology (EAN) Annual Meeting, in Copenhagen.

The following data will be presented by Eric J. Pappert, M.D., Vice President Global Medical Affairs, Cynapsus Therapeutics, today from 12:30-13:15 p.m. CET.

Poster Presentations

1. Apomorphine Film (APL-130277) Produces No Buccal Mucosal Irritation: Results from a 28-Day Toxicology Study in Hamsters (Poster #31123)
   • 28-day toxicology study in 16 hamsters
   • APL-130277, Cynapsus' apomorphine film, produced no irritation of the cheek pouch buccal mucosal of male and female hamsters when administered at a dose of 2.08 mg (15 times higher than a 30 mg dose in a 60 kg human) three times daily for 28 consecutive days
     
     
2. Treatments of OFF Episodes in Parkinson's Disease: An Evaluation of Physician Practices (Poster #31122)
   • Responses from 120 caregivers and patients on the impact of OFF episodes on quality of life (QoL) and satisfaction with current patient treatment
   • 32.6% of patients and caregivers indicated that they had OFF episodes in the first year post diagnosis
   • 53.3% of patients and caregivers indicating that OFF episodes started 2-3 years post diagnosis
   • Patients and caregivers reported that OFF episodes had a negative impact on QoL
     
     
3. The Treatment of OFF Episodes in Parkinson's Disease: An Evaluation of Patient and Caregiver Insights (Poster #31121)
   • 102 physicians who treat patients with PD were queried on their practices and attitudes regarding the treatment of OFF episodes
   • Physicians are concerned about OFF episodes and feel that their patients are aware of OFF episodes
   • Physicians feel that there is a fairly high level of unmet need regarding treatment options for OFF episodes

The posters will be accessible from Cynapsus' corporate website at www.cynapsus.ca.